Navitoclax (ABT-263)

Name: Navitoclax (ABT-263)
Brand: Selleck Chemicals
SKU: S1001
Rating: 5 (186 reviews)

For research use only.

Catalog No.S1001

186 publications

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Selleck's Navitoclax (ABT-263) has been cited by 186 publications

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Nat Cell Biol, 2020, 4

PubMed: 32367049 ( click the link to review the publication )

Sci Transl Med, 2020, 15;12(539) pii: eaax3799

PubMed: 32295900 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Blood Cancer J, 2020, 10(6):72

PubMed: 32591499 ( click the link to review the publication )

Aging Cell, 2020, 19(4):e13133

PubMed: 32175667 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )
Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):443

PubMed: 32513939 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(3):e0008150

PubMed: 32196500 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):222

PubMed: 31937836 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Laryngoscope, 2020, 10.1002

PubMed: 31894587 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Biomater Sci, 2020, 8(8):2264-2273

PubMed: 32134074 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 15;106(4):867-877

PubMed: 31786278 ( click the link to review the publication )

Free Radic Biol Med, 2020, 152:227-234

PubMed: 32217194 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )
Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Nat Metab, 2019, 1(11):1074-1088

PubMed: 31799499 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )
Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )
Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Cell Discov, 2017, 3:16048

PubMed: 28101374 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )
Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )
Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )
Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHscFVnUUN3ME2wMlAxPjZ7IN88US=>	Mm\uV2FPT0WU
MV-4-11	NWnhN2dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvHTWM2OD1yLkCxOVg3KM7:TR?=	MV7TRW5ITVJ?
NKM-1	NX7sXYRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHCbXVKSzVyPUCuNFE3QTlizszN	NF7sXFhUSU6JRWK=
ML-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3YTWM2OD1yLkCxPVg{KM7:TR?=	MmXaV2FPT0WU
BV-173	NHnyZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnl[4hKSzVyPUCuNFI{OTRizszN	NF;3UFNUSU6JRWK=
RS4-11	NIS4RYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTwfWlKSzVyPUCuNFI2QDdizszN	NGCzXWZUSU6JRWK=
HL-60	NHq3SWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\pWGlEPTB;MD6wNlkxQCEQvF2=	NFX4R21USU6JRWK=
KY821	NYHzbWlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMEK5O\|Uh\|ryP	NFzYSphUSU6JRWK=
ECC10	NF;vR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[z[I9KSzVyPUCuNFM4QTJizszN	Mn;vV2FPT0WU
NCI-H720	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3O2TWlEPTB;MD6wOFAyOSEQvF2=	NYXMd\|VKW0GQR1XS
QIMR-WIL	NG\OZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMESyPFch\|ryP	MVHTRW5ITVJ?
KG-1	NFP0U4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjCfoRKSzVyPUCuNFQ1QDZizszN	NYryNFBKW0GQR1XS
TGW	MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjNSm54UUN3ME2wMlA1PjN\|IN88US=>	NX7YfplUW0GQR1XS
ATN-1	NFXDXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXGO5pKSzVyPUCuNFQ4OzNizszN	MY\TRW5ITVJ?
RH-18	NVXTO5duT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwME[wOFgh\|ryP	NXuwPYNGW0GQR1XS
EW-18	NEC5eJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwME[4OFEh\|ryP	M1TPVXNCVkeHUh?=
NB17	NXLRd3FIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfFbmtiUUN3ME2wMlA4OTJ2IN88US=>	NEniSHBUSU6JRWK=
SK-NEP-1	NYS2eZFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3DW5NKSzVyPUCuNFczOTNizszN	M{OydnNCVkeHUh?=
P12-ICHIKAWA	NHfHUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXNfFJ7UUN3ME2wMlA4Pzd6IN88US=>	M3zYPXNCVkeHUh?=
KARPAS-45	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HBeGlEPTB;MD6wO\|gyPSEQvF2=	NFPlRlJUSU6JRWK=
EW-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn75TWM2OD1yLkC4NFU{KM7:TR?=	M4qxWXNCVkeHUh?=
NB13	NFu0UFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MontTWM2OD1yLkC4NlA{KM7:TR?=	MXvTRW5ITVJ?
NCI-H209	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMEi3NFQh\|ryP	NVS2SXlpW0GQR1XS
NCI-H1092	NX7O[WRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XGZmlEPTB;MD6xNFI4PSEQvF2=	M37DUXNCVkeHUh?=
NH-12	NHP2T\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXLR29KSzVyPUCuNVA4PDRizszN	NXT1c4VjW0GQR1XS
697	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2K0VWlEPTB;MD6xNFg{QSEQvF2=	NHvJeGRUSU6JRWK=
KE-37	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37y[GlEPTB;MD6xNVM4KM7:TR?=	MVvTRW5ITVJ?
MOLT-4	M1eyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwMUWxOlkh\|ryP	M2jyXHNCVkeHUh?=
CHP-134	NVjuWZlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTZXWxIUUN3ME2wMlE3OzB4IN88US=>	MnrEV2FPT0WU
D-283MED	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{L2ZWlEPTB;MD6xO\|Y5PiEQvF2=	M2\PbnNCVkeHUh?=
LU-135	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILKVGlKSzVyPUCuNVg2PTJizszN	NGHTNXFUSU6JRWK=
LU-134-A	NH25VI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrqbVhmUUN3ME2wMlE5PjdzIN88US=>	NYXJTnNqW0GQR1XS
EM-2	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3e0O2lEPTB;MD6xPVkyQCEQvF2=	M4jJV3NCVkeHUh?=
LU-139	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMkC0PVgh\|ryP	MUDTRW5ITVJ?
ALL-PO	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwMkG5PFgh\|ryP	MlOwV2FPT0WU
NB12	NH7HO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX64XXNCUUN3ME2wMlI{OTF3IN88US=>	M2TTTXNCVkeHUh?=
KP-N-YN	NEnYWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzwU2JoUUN3ME2wMlI{PTd\|IN88US=>	M1\yNnNCVkeHUh?=
BEN	M2HPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwMkO5Olgh\|ryP	MUDTRW5ITVJ?
HCC1569	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF25dpVKSzVyPUCuNlUyODZizszN	M{nnbnNCVkeHUh?=
HuO9	NYfPXXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTMfm5mUUN3ME2wMlI3PzF3IN88US=>	NIDyephUSU6JRWK=
WM-115	NF\sSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF6zepVKSzVyPUCuNlc4OzhizszN	M3\mfHNCVkeHUh?=
CCRF-CEM	NVTiTmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nLN2lEPTB;MD6zN\|UzQSEQvF2=	NUDqboozW0GQR1XS
IST-SL1	NHHzfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfMTWM2OD1yLkO1N\|Q{KM7:TR?=	NYK4cpc3W0GQR1XS
BE-13	Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml6zTWM2OD1yLkO2OFU6KM7:TR?=	NX60SWVLW0GQR1XS
COR-L88	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwM{[1OEDPxE1?	NIC5RlNUSU6JRWK=
DOHH-2	NF7LdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DuZWlEPTB;MD60NVAzOyEQvF2=	MnKxV2FPT0WU
A704	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwNEK2O{DPxE1?	NYPp[4ZoW0GQR1XS
KNS-81-FD	NIXOOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrISFJzUUN3ME2wMlQ1ODF5IN88US=>	MUPTRW5ITVJ?
RPMI-8226	M{HJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHyzZ\|hKSzVyPUCuOFU3PTJizszN	MnKyV2FPT0WU
TGBC24TKB	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIf2e3RKSzVyPUCuOFU4PzhizszN	MoPTV2FPT0WU
NCI-H1304	NXfkbZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfXZ2RKSzVyPUCuOFYyPTdizszN	MWXTRW5ITVJ?
MOLT-13	M{\MPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXtbHhxUUN3ME2wMlQ3PjF\|IN88US=>	M4L3VXNCVkeHUh?=
EW-22	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm[0TWM2OD1yLkS2OlcyKM7:TR?=	MnLZV2FPT0WU
MS-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfjSIVuUUN3ME2wMlQ3QTN\|IN88US=>	MV;TRW5ITVJ?
RMG-I	NVTBW2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwNEm0OlQh\|ryP	NHPvSphUSU6JRWK=
NTERA-S-cl-D1	NXntbJlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwNUCwNVkh\|ryP	MkLpV2FPT0WU
NCI-H1048	MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDGTWM2OD1yLkWwPVU{KM7:TR?=	M4j3bHNCVkeHUh?=
SW1417	NGjIS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwNUW0N\|gh\|ryP	NU\zWIFvW0GQR1XS
DB	Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\zNGlEPTB;MD61O\|A5KM7:TR?=	MVLTRW5ITVJ?
MEG-01	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDvZohKSzVyPUCuOVg{OiEQvF2=	M{HIVnNCVkeHUh?=
EW-13	NIi3NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwNUizOFEh\|ryP	M{HFbXNCVkeHUh?=
LAMA-84	M3vEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwNUmyNFch\|ryP	NUKyRZdQW0GQR1XS
J-RT3-T3-5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli4TWM2OD1yLk[wPFA5KM7:TR?=	M{\xO3NCVkeHUh?=
MOLT-16	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f5e2lEPTB;MD62OVI3PCEQvF2=	NWXEbYJyW0GQR1XS
DU-4475	M4HrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYW4PVVMUUN3ME2wMlY2PDJ5IN88US=>	MoDoV2FPT0WU
HAL-01	M3fGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ewbmlEPTB;MD63NlU1QSEQvF2=	M1zNO3NCVkeHUh?=
RD	M1K5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnkN\|ZKSzVyPUCuO\|U5QTlizszN	MX7TRW5ITVJ?
OAW-28	NXr4OpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzkTWM2OD1yLke4N\|ch\|ryP	MnjwV2FPT0WU
HCC38	NF3G[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwOECxPUDPxE1?	MnWwV2FPT0WU
NMC-G1	Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fmXGlEPTB;MD64NVEzOSEQvF2=	MlvRV2FPT0WU
EW-16	M{\VSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHWTWM2OD1yLkixN\|I5KM7:TR?=	MVTTRW5ITVJ?
DU-145	NUfmcY81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7LTWM2OD1yLki5PVI{KM7:TR?=	M1;1dXNCVkeHUh?=
HPAF-II	M1\LeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHm1[WpKSzVyPUCuPVI3OjhizszN	MUfTRW5ITVJ?
A427	NYXDT\|diT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwOUOwNlIh\|ryP	MYDTRW5ITVJ?
PA-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\3TWM2OD1yLkm1OlQzKM7:TR?=	M1y0XXNCVkeHUh?=
OAW-42	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlKzTWM2OD1yLkm2NVQ3KM7:TR?=	NV7PSFgxW0GQR1XS
L-428	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\WTWM2OD1zLkCxNlUh\|ryP	MnLhV2FPT0WU
COLO-824	NIrEV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjtTWM2OD1zLkCxO\|A5KM7:TR?=	M3;uOXNCVkeHUh?=
P30-OHK	NFnnSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3n6cGlEPTB;MT6wOFY5QCEQvF2=	NVKxdI5UW0GQR1XS
NCI-H2170	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPoTWM2OD1zLkC2NlMh\|ryP	MWrTRW5ITVJ?
HCC2998	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\HOVVCUUN3ME2xMlA4OTN3IN88US=>	NUO5RVlHW0GQR1XS
NB14	NF[wRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVP3d3lMUUN3ME2xMlE{PzR6IN88US=>	MlHyV2FPT0WU
TGBC1TKB	M1Gxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTFwMUSxOVIh\|ryP	M3TOdnNCVkeHUh?=
KP-N-YS	NWLmbmNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPaSlRKSzVyPUGuNVYzOzZizszN	NYXIWYN2W0GQR1XS
CAL-120	NG\adYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjHbIZKSzVyPUGuNVY1OjlizszN	NIXnRoJUSU6JRWK=
SBC-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TuemlEPTB;MT6xPVA2OyEQvF2=	M1\iVnNCVkeHUh?=
C32	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVz6WI9GUUN3ME2xMlE6ODh6IN88US=>	NGHOSVdUSU6JRWK=
HCC2157	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULuVGkxUUN3ME2xMlE6PDl2IN88US=>	NWTQfWhiW0GQR1XS
COLO-792	NV\Xe3g3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jRRWlEPTB;MT6yNFA4OSEQvF2=	MmTUV2FPT0WU
ES7	M3;OWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLhUmc1UUN3ME2xMlI4QTVzIN88US=>	NUPvVZJSW0GQR1XS
HEL	NWLoNJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHEWJJKSzVyPUGuN\|ExOjlizszN	M3rHb3NCVkeHUh?=
ES4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTFwM{S5PVgh\|ryP	NXPmSYtmW0GQR1XS
NCI-SNU-1	NUDqT29[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTFwM{[1OVUh\|ryP	NYSyPHJzW0GQR1XS
MDA-MB-415	NYWxd4FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4njNmlEPTB;MT6zPFg2KM7:TR?=	MX;TRW5ITVJ?
NCI-H2342	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHBNldKSzVyPUGuOFAzPjlizszN	MYHTRW5ITVJ?
NB69	MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrk[5JTUUN3ME2xMlQ3OjdzIN88US=>	NYrweWx[W0GQR1XS
D-247MG	NU\ZPZplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTFwNUGxNlIh\|ryP	NV60TJJtW0GQR1XS
SCC-4	NIjDcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fJcGlEPTB;MT61PVg5PyEQvF2=	NHy2UnFUSU6JRWK=
HuH-7	NVfidpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfjPJdKSzVyPUGuOlczQTNizszN	NFTYRVNUSU6JRWK=
A388	M3XacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEWyeJRKSzVyPUGuOlg4OjRizszN	M1nj[nNCVkeHUh?=
Calu-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnyTWM2OD1zLkewOlk4KM7:TR?=	MYDTRW5ITVJ?
NCI-H1648	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlj5TWM2OD1zLkexOFE5KM7:TR?=	M4fPPXNCVkeHUh?=
NCI-H2052	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTFwN{KyNFEh\|ryP	NF;FdHBUSU6JRWK=
Ramos-2G6-4C10	M4rPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTFwN{O2OVYh\|ryP	M4qwSHNCVkeHUh?=
DEL	NF\1[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LLPGlEPTB;MT63OFY6OiEQvF2=	MlzSV2FPT0WU
SNU-423	MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofvTWM2OD1zLke4NVU4KM7:TR?=	NHP3T3dUSU6JRWK=
COR-L23	NYrUW4VQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTFwN{m4O\|Qh\|ryP	MkXiV2FPT0WU
OMC-1	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlv0TWM2OD1zLki2NFE3KM7:TR?=	NW\NfIpQW0GQR1XS
EW-11	NUjzcI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj6VnByUUN3ME2xMlk2PjV5IN88US=>	Mny2V2FPT0WU
HSC-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXJbnR4UUN3ME2xMlk3OzZ3IN88US=>	MWTTRW5ITVJ?
MLMA	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTFwOU[2O\|ch\|ryP	NVvXfWhSW0GQR1XS
RCM-1	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHJTWM2OD1{LkCwN\|k6KM7:TR?=	Moj6V2FPT0WU
MFE-280	NHLzUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTJwMEK4OFgh\|ryP	NY\vXJpnW0GQR1XS
ES8	M3fyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHodIdpUUN3ME2yMlI2PDdzIN88US=>	M3\2RnNCVkeHUh?=
TE-11	M1PUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPaTWM2OD1{LkK5OFc{KM7:TR?=	NVrSXGlrW0GQR1XS
HuO-3N1	NETHdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTJwNEi3PEDPxE1?	MoPIV2FPT0WU
MHH-NB-11	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jreWlEPTB;Mj61NVE2QCEQvF2=	NH;tcm5USU6JRWK=
TGBC11TKB	NGjQO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjvUVBKSzVyPUKuOVc3QDFizszN	NWTlWoRSW0GQR1XS
HOP-92	NYX2R2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NImwSnRKSzVyPUKuOVg4PDNizszN	M{PkfHNCVkeHUh?=
IGR-1	M{TEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTJwNkKwN\|Uh\|ryP	NEfWO2dUSU6JRWK=
GOTO	NGfZVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfKTWM2OD1{Lk[1N\|c4KM7:TR?=	M1fiUHNCVkeHUh?=
NCI-H1650	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvUTWM2OD1{LkeyNlE2KM7:TR?=	Ml;pV2FPT0WU
NCI-H1581	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rxfWlEPTB;Mj63PVY5OSEQvF2=	M3vxUHNCVkeHUh?=
NCI-H2405	MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLRZnhEUUN3ME2yMlgzPzh{IN88US=>	M1jRe3NCVkeHUh?=
U-118-MG	NEK1O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTJwOU[0PVEh\|ryP	NYX5VIFjW0GQR1XS
DoTc2-4510	M2[0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHj5emVKSzVyPUOuNFE1OTdizszN	M2fhdXNCVkeHUh?=
NCI-H596	M1m4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\0OItKSzVyPUOuNFQ6QTdizszN	MX7TRW5ITVJ?
MPP-89	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\N[nRCUUN3ME2zMlA2PjZ4IN88US=>	NE\iS\|FUSU6JRWK=
GCIY	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzNNpM1UUN3ME2zMlIxPDlzIN88US=>	M2rlc3NCVkeHUh?=
SW626	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jB[2lEPTB;Mz6yOFU1OyEQvF2=	MUnTRW5ITVJ?
OCI-AML2	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2POV2lEPTB;Mz6zNVI4OiEQvF2=	MVLTRW5ITVJ?
NBsusSR	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXUN2xKSzVyPUOuN\|Q6OzhizszN	MnLnV2FPT0WU
AN3-CA	NWXMd4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDPTWM2OD1\|LkS0NlM5KM7:TR?=	MlzVV2FPT0WU
EFM-19	M4LITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnqxTWM2OD1\|LkS4N\|M6KM7:TR?=	MoX5V2FPT0WU
RVH-421	NGPRWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTNwNU[4O\|ch\|ryP	MWXTRW5ITVJ?
5637	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHYPXVWUUN3ME2zMlYyOTB\|IN88US=>	M4fWRXNCVkeHUh?=
PANC-08-13	MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmS0TWM2OD1\|Lk[zOFczKM7:TR?=	NVn4doJnW0GQR1XS
H9	NFS4c\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTNwNkexOFQh\|ryP	NFfJUWFUSU6JRWK=
KARPAS-299	NY\HNVdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\FdotKSzVyPUOuOlc{PjFizszN	MnrqV2FPT0WU
TE-5	NVT4Vm1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\vb\|ZqUUN3ME2zMlcxPzB7IN88US=>	NHP4c\|NUSU6JRWK=
NOS-1	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP5VY1KSzVyPUOuO\|k5OzRizszN	MkHOV2FPT0WU
HH	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\XeHZqUUN3ME2zMlg{QDZ6IN88US=>	NVXPNVloW0GQR1XS
769-P	M{nUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LSWmlEPTB;Mz64PVUyKM7:TR?=	M2rCcnNCVkeHUh?=
CHP-212	M4TF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fDOGlEPTB;Mz65NlU1QSEQvF2=	MlzuV2FPT0WU
NCI-H82	M{mzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDQTWM2OD1\|Lkm1PVM3KM7:TR?=	MX3TRW5ITVJ?
Mo-T	Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XncGlEPTB;ND6wOFMyOiEQvF2=	NHnHb3RUSU6JRWK=
BB65-RCC	NIjqO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTRwMESzPVkh\|ryP	NGjlSY1USU6JRWK=
SW1990	NHr5SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTRwMEW5NFgh\|ryP	NXnWd\|RFW0GQR1XS
LK-2	NX\jdnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\RPItKSzVyPUSuNVEzQTNizszN	NX\IO2RoW0GQR1XS
ES5	NYK5W3JIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTXTWM2OD12LkGzPVg2KM7:TR?=	NVXo[5RWW0GQR1XS
JVM-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnybVJKSzVyPUSuNVgzOjJizszN	MorGV2FPT0WU
RPMI-7951	M{f3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLydJBKSzVyPUSuNlI1OTNizszN	NILGPIxUSU6JRWK=
Calu-6	M3rzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHyc4JKSzVyPUSuNlc5QDFizszN	M3jXenNCVkeHUh?=
LC-2-ad	Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TrR2lEPTB;ND6yPVU3QCEQvF2=	MnHIV2FPT0WU
SW954	MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\GTWM2OD12LkK5OlYh\|ryP	MYXTRW5ITVJ?
H-EMC-SS	NYrueZIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn2wTWM2OD12LkOxPFMyKM7:TR?=	NHTwWYRUSU6JRWK=
ES3	NU[1XIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn71TWM2OD12LkO1OFQyKM7:TR?=	M1\BNXNCVkeHUh?=
no-11	M4ftR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;ETWM2OD12LkO1OVU1KM7:TR?=	NXHsVXltW0GQR1XS
LAN-6	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\4T2tKSzVyPUSuOFUyQDlizszN	M1TOfnNCVkeHUh?=
FTC-133	NVrBXo5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHOdZlPUUN3ME20MlU{QTVizszN	MmCyV2FPT0WU
8505C	NGDLXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\4TWM2OD12LkW0NlMh\|ryP	MoLEV2FPT0WU
SW620	NVTXcnBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlG3TWM2OD12LkW3NFU4KM7:TR?=	NILDe\|dUSU6JRWK=
BCPAP	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYP0dpp[UUN3ME20MlY{PDhzIN88US=>	NUO2T2ZoW0GQR1XS
SK-LU-1	Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTRwNk[wPFkh\|ryP	M1HDOnNCVkeHUh?=
NCI-H1623	NFfYWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TW[WlEPTB;ND63NFIzQCEQvF2=	M3X0cHNCVkeHUh?=
C2BBe1	NVTQVXNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTRwN{SwNFgh\|ryP	NGn5[5JUSU6JRWK=
GP5d	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTRwN{izPFgh\|ryP	MVTTRW5ITVJ?
NB6	NHXJdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHZ[pRKSzVyPUSuPFYzODRizszN	NIXEPIVUSU6JRWK=
MDA-MB-157	MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWWyepp6UUN3ME20Mlg5PzZizszN	MWPTRW5ITVJ?
UMC-11	M1vIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXITWM2OD12Lki4PVY1KM7:TR?=	NF;GSGhUSU6JRWK=
HCC1419	NWDDd2hIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1W0UmlEPTB;ND65NFA3OyEQvF2=	MlH6V2FPT0WU
NCI-H2029	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTRwOUSxPFUh\|ryP	NYXKN29KW0GQR1XS
LXF-289	NImyUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTVwMEO3NVkh\|ryP	NGC3PVJUSU6JRWK=
KINGS-1	NEDUbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTVwMEe3OFQh\|ryP	NInmUJBUSU6JRWK=
HD-MY-Z	NVvuUI44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTVwMkO5Olkh\|ryP	M1\WTXNCVkeHUh?=
ESS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTVwMkW1PVch\|ryP	NUfK[mVLW0GQR1XS
GI-1	NWO5OItHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInqOGVKSzVyPUWuNlc6OjZizszN	NULoXVd1W0GQR1XS
RPMI-2650	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfITWM2OD13LkO2NVYh\|ryP	MkjiV2FPT0WU
IA-LM	NHvyOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\mT2lEPTB;NT6zPVg4OSEQvF2=	MUTTRW5ITVJ?
KP-4	NWPz[HdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrXTHV[UUN3ME21MlQ3OzN2IN88US=>	NUG3S483W0GQR1XS
G-402	NETnS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3e0OWlEPTB;NT61NVg3PSEQvF2=	NYDaUIZ{W0GQR1XS
OS-RC-2	MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTVwNUK2NFQh\|ryP	NHyyTY9USU6JRWK=
NCI-H1155	MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHrTWM2OD13LkW0PVU2KM7:TR?=	MXzTRW5ITVJ?
OE19	MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TqV2lEPTB;NT62PFYzPCEQvF2=	MnLiV2FPT0WU
U-2-OS	NFLXPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHLTWM2OD13Lki5NFE{KM7:TR?=	M4HsSnNCVkeHUh?=
SCC-15	MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fHSWlEPTB;NT65N\|Y3OiEQvF2=	NYraNZM6W0GQR1XS
NCI-H630	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnztTWM2OD13Lkm5OFA1KM7:TR?=	MV;TRW5ITVJ?
PFSK-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmT3TWM2OD14LkC1NlU6KM7:TR?=	NH;LfZdUSU6JRWK=
NCI-H1770	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PYNGlEPTB;Nj6yNFg4PCEQvF2=	M2PhZnNCVkeHUh?=
SK-MEL-3	NWCxTYlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEOxSVRKSzVyPU[uOFI6OTVizszN	NUjNenl6W0GQR1XS
LB1047-RCC	M13QeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTZwNEe2NlUh\|ryP	M2P3TnNCVkeHUh?=
NCI-H446	M3raXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHwVms2UUN3ME22MlYzQTJ3IN88US=>	MXnTRW5ITVJ?
SW780	NX\lWGpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmexTWM2OD14LkewNVg2KM7:TR?=	NG\RVYVUSU6JRWK=
NEC8	NXHGbGI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTZwN{[2N{DPxE1?	MXXTRW5ITVJ?
NOMO-1	NVSwdHJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;Pe24xUUN3ME22Mlc5OTFzIN88US=>	NWHu[VFjW0GQR1XS
COLO-668	NGXSbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHraR4hKSzVyPU[uPFQ{QDdizszN	NHLXXIhUSU6JRWK=
MC116	NWHLO5o4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPHcIRKSzVyPU[uPVM5QTdizszN	MULTRW5ITVJ?
HCC1937	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjTTWM2OD14Lkm5NlUyKM7:TR?=	MUjTRW5ITVJ?
NCI-N87	NXTmNJlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTdwMUmyPVMh\|ryP	NVvwc2hpW0GQR1XS
COLO-320-HSR	NFPrcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrhXnNUUUN3ME23MlIzPzN6IN88US=>	NX;GZoxuW0GQR1XS
HCC1806	NEHuclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M12zb2lEPTB;Nz6yOlA1PCEQvF2=	NV:xfno4W0GQR1XS
OVCAR-3	MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fzXGlEPTB;Nz6zN\|A{QCEQvF2=	NVzBOIRPW0GQR1XS
NUGC-3	NHLn[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTdwM{m2PVQh\|ryP	MWjTRW5ITVJ?
SW1783	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPYWodRUUN3ME23MlQ{OTd3IN88US=>	NX7GUXhRW0GQR1XS
GCT	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTdwNU[5NFYh\|ryP	NX\wXph5W0GQR1XS
NCI-H2126	NV7kb4lmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\jTmlEPTB;Nz63N\|YzPSEQvF2=	MmrXV2FPT0WU
MEL-HO	M4DKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXmcWtPUUN3ME23Mlc4ODV2IN88US=>	MWfTRW5ITVJ?
CAPAN-1	NXPZ[VNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zUPGlEPTB;Nz63O\|M2PyEQvF2=	NEnYeFFUSU6JRWK=
SW756	NIDJSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfXTWM2OD15Lke4N\|M{KM7:TR?=	NX;uT2NoW0GQR1XS
SKG-IIIa	NUS4RYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTdwOEG4PVIh\|ryP	Mm\kV2FPT0WU
HCE-T	M1qy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrKTWM2OD15Lki3O\|g{KM7:TR?=	NX[2cmF6W0GQR1XS
Ca-Ski	M3jHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUn3OmtxUUN3ME23Mlk6Ozh\|IN88US=>	MVHTRW5ITVJ?
COLO-684	M1Ha[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRThwMEG4NVgh\|ryP	MnjHV2FPT0WU
KYSE-70	M3rpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XpR2lEPTB;OD6wO\|czQSEQvF2=	MWHTRW5ITVJ?
TI-73	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFSxdndKSzVyPUiuNlU5PTFizszN	Mme5V2FPT0WU
BT-20	NYTIPVM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRThwMk[wOVIh\|ryP	MmHLV2FPT0WU
MHH-ES-1	NELPVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rZbmlEPTB;OD61NVg{PCEQvF2=	MYXTRW5ITVJ?
TE-12	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTyW2pEUUN3ME24MlU6QTNzIN88US=>	MYTTRW5ITVJ?
YH-13	NWr5c3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX2wNnBGUUN3ME24MlYyODB6IN88US=>	NIjCOWdUSU6JRWK=
SF126	NELSdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz6d2Z{UUN3ME24Mlg{QDZ3IN88US=>	M1zzW3NCVkeHUh?=
J82	NVjO[5VWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXKwT2w3UUN3ME24MlkxODN6IN88US=>	MWXTRW5ITVJ?
RCC10RGB	NXjCT\|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jr[GlEPTB;OD65PVU3OSEQvF2=	MknNV2FPT0WU
SK-UT-1	M2nxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDLWHpKSzVyPUmuNFQ6PDVizszN	MmnUV2FPT0WU
LB2241-RCC	M3\KfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PmNmlEPTB;OT6xPVE{PyEQvF2=	NHPidFVUSU6JRWK=
LB996-RCC	NFnkdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTwW4lKSzVyPUmuNVk5QSEQvF2=	M1fyfXNCVkeHUh?=
EPLC-272H	MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HLPWlEPTB;OT6zO\|Y2PyEQvF2=	MkK0V2FPT0WU
CTV-1	NHjLVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHENFd[UUN3ME25MlU3PTN{IN88US=>	Ml;TV2FPT0WU
HSC-2	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXwXplKSzVyPUmuOVc2PSEQvF2=	M37VenNCVkeHUh?=
SK-MEL-28	M3PZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDWUmhKSzVyPUmuOlE5QTNizszN	MlnlV2FPT0WU
MMAC-SF	NV;4enJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\P[GZKSzVyPUmuOlg4PSEQvF2=	M2exSHNCVkeHUh?=
CP50-MEL-B	M4CzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTFdZJEUUN3ME25Mlc2Pzh{IN88US=>	MmHBV2FPT0WU
HT-1080	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfUUYtZUUN3ME25Mlc4PzN7IN88US=>	NXfwWZN1W0GQR1XS
HEC-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHCZYZKSzVyPUGwMlM{PTJizszN	NHGyc\|JUSU6JRWK=
AGS	MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFyLkO3OEDPxE1?	NY\l[4hQW0GQR1XS
GAMG	M1yxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjaSGtKSzVyPUGwMlUyPjJizszN	Mn3YV2FPT0WU
SW48	M17Wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;VTWM2OD1zMD61NVg6KM7:TR?=	M2rIW3NCVkeHUh?=
U031	NXO1cI5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPzTWM2OD1zMD61PVA5KM7:TR?=	MY\TRW5ITVJ?
OVCAR-5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInTO3hKSzVyPUGwMlY1OjlizszN	NH\DR2pUSU6JRWK=
SF295	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7sToNPUUN3ME2xNE43PzB2IN88US=>	NGfqU\|ZUSU6JRWK=
BHT-101	NUjY[JM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjTTZFlUUN3ME2xNE44OTd5IN88US=>	MY\TRW5ITVJ?
VMRC-RCZ	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX[0S3NqUUN3ME2xNU4{OjBzIN88US=>	M2\uS3NCVkeHUh?=
ACHN	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTvXlVmUUN3ME2xNU41OjFzIN88US=>	NGDoOotUSU6JRWK=
NCI-H526	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTFzLkWwOFMh\|ryP	NWruRYZCW0GQR1XS
MN-60	NFPhd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXhe\|VKSzVyPUGxMlU{QSEQvF2=	MXXTRW5ITVJ?
NCI-H2291	M4SwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\tb2lEPTB;MUGuOVQ3PiEQvF2=	M4\TOXNCVkeHUh?=
SCC-25	M4C1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjtRohRUUN3ME2xNU44PTV4IN88US=>	NFW1VndUSU6JRWK=
SK-MEL-2	NETQO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2j4WGlEPTB;MUGuO\|Y{PyEQvF2=	NFq5[mhUSU6JRWK=
SN12C	NELhSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fW[mlEPTB;MUGuPVM2PSEQvF2=	MljrV2FPT0WU
NCI-H69	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\Oe3FlUUN3ME2xNk41OjN2IN88US=>	MnS5V2FPT0WU
ME-180	M4P5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTF{LkewOVQh\|ryP	MoK5V2FPT0WU
MC-IXC	M2C5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzndVZKSzVyPUGyMlc2OThizszN	NXTQXGRJW0GQR1XS
NCI-H2347	NVHtZWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;jPZJCUUN3ME2xNk44PjF2IN88US=>	MkizV2FPT0WU
M059J	NVPtenU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXicGFKSzVyPUGyMlc4OjdizszN	NVTBTIFwW0GQR1XS
A2058	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzYS\|BKSzVyPUGyMlg3QDFizszN	M3WyT3NCVkeHUh?=
VA-ES-BJ	NEHycWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHuyXmpKSzVyPUGyMlg4QDVizszN	MUXTRW5ITVJ?
Ca9-22	M1XxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLsfZNKSzVyPUGyMlk1PTFizszN	NF;sV49USU6JRWK=
KNS-42	NGLEfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTXTWM2OD1zMj65PVg1KM7:TR?=	MVPTRW5ITVJ?
LoVo	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXeyWlZkUUN3ME2xN{4zOzF\|IN88US=>	MkPxV2FPT0WU
AM-38	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXke\|JKSzVyPUGzMlI2PjZizszN	MYfTRW5ITVJ?
NB5	NY\Ub3dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2[xO2lEPTB;MUOuN\|c2OiEQvF2=	MV;TRW5ITVJ?
L-363	NGK5c5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTF\|LkSwN\|Mh\|ryP	M{[yR3NCVkeHUh?=
SK-MEL-30	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoeyTWM2OD1zND6wOlQ2KM7:TR?=	NXXaT2tGW0GQR1XS
NCI-H1563	NWDLdpJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTGTWM2OD1zND62NFM6KM7:TR?=	MnHPV2FPT0WU
NCI-H2228	NH71N\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r6emlEPTB;MUSuOlA4PyEQvF2=	MXPTRW5ITVJ?
MFM-223	NV64XYxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTF3LkG4NVMh\|ryP	MUXTRW5ITVJ?
LB831-BLC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHmPFJQUUN3ME2xOU4zPzZ5IN88US=>	MX7TRW5ITVJ?
SW872	M1nrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnGwTWM2OD1zNT6zNFg3KM7:TR?=	NV:5e\|RjW0GQR1XS
NCI-H522	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XKU2lEPTB;MUWuN\|MxPiEQvF2=	MXXTRW5ITVJ?
EW-1	M1jXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPJTWM2OD1zNT61OFYzKM7:TR?=	M2PJ[nNCVkeHUh?=
HN	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[0Vm5KSzVyPUG1MlU6PDJizszN	Ml;HV2FPT0WU
SW837	M3X1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;KSmZKSzVyPUG1Mlc5PDdizszN	MYHTRW5ITVJ?
SCC-9	M17i[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorVTWM2OD1zNT64NVE1KM7:TR?=	M1;OWXNCVkeHUh?=
MKN7	MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTF3Lkm3N\|Ih\|ryP	NGL0eXZUSU6JRWK=
KYSE-410	M1HlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLKTWM2OD1zNj61PVEh\|ryP	MkH0V2FPT0WU
SK-N-DZ	NUPNNWI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTF4Lk[xNVYh\|ryP	M3Pj[HNCVkeHUh?=
COR-L105	MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nveWlEPTB;MU[uOlUzQCEQvF2=	M161U3NCVkeHUh?=
LB2518-MEL	NXHlfnBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvqNYZtUUN3ME2xOk45Ozh7IN88US=>	M1jsSnNCVkeHUh?=
OVCAR-4	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTF4Lki4OlIh\|ryP	NGTSPGlUSU6JRWK=
TK10	NHHSToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTF4Lkm0O\|Mh\|ryP	MnW0V2FPT0WU
KNS-62	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTF4Lkm3O\|ch\|ryP	M3zvRnNCVkeHUh?=
RPMI-8866	M1fZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;hZo51UUN3ME2xO{4yPzN{IN88US=>	M4jpeXNCVkeHUh?=
HuP-T4	NX;OUHJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXsTWM2OD1zNz6yOFk2KM7:TR?=	NYnUc\|FoW0GQR1XS
CGTH-W-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTF5LkWyNVkh\|ryP	MUTTRW5ITVJ?
T-24	NGfPNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\xb5VKSzVyPUG3MlU{PDdizszN	MlS0V2FPT0WU
HT-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTF5LkW5NVQh\|ryP	MVnTRW5ITVJ?
KS-1	NHPpUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTF5Lk[3N{DPxE1?	M{ToenNCVkeHUh?=
NCI-H1792	M3jNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTF5Lke5PEDPxE1?	M1n0bHNCVkeHUh?=
ABC-1	NHzmXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPNeGdKSzVyPUG3MlgyPDFizszN	MX7TRW5ITVJ?
BPH-1	NWHzcYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3z5bmlEPTB;MUiuNVY5PSEQvF2=	Mn25V2FPT0WU
A431	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm[wTWM2OD1zOD60NVI4KM7:TR?=	Ml7UV2FPT0WU
T98G	NWDVRlRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLuOopPUUN3ME2xPE42OTV5IN88US=>	MojiV2FPT0WU
BHY	M3TvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFG0NIpKSzVyPUG4Mlg3QSEQvF2=	NFT0TlJUSU6JRWK=
Capan-2	M{G1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn63TWM2OD1zOD65NFc5KM7:TR?=	M1nxWnNCVkeHUh?=
MDA-MB-175-VII	NYK2RVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLaTWM2OD1zOD65NlA6KM7:TR?=	MVLTRW5ITVJ?
CAL-27	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTF7LkC0PFch\|ryP	MYPTRW5ITVJ?
AsPC-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnw[mtHUUN3ME2xPU45PjV5IN88US=>	NGjEXlJUSU6JRWK=
KU812	NW\BXlZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnSU25KSzVyPUG5Mlk2PzNizszN	NEDXV\|BUSU6JRWK=
NCI-H441	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LEO2lEPTB;MkCuNFAyKM7:TR?=	NX2zSG9kW0GQR1XS
Mewo	M2T0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37WemlEPTB;MkCuNVI5QCEQvF2=	MmTmV2FPT0WU
SK-MEL-24	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvVZW1KSzVyPUKwMlE1PzdizszN	M{XpfHNCVkeHUh?=
NCI-H727	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLDTWM2OD1{MD6yO\|A1KM7:TR?=	MYrTRW5ITVJ?
EKVX	M1:xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\6d4FZUUN3ME2yNE43ODZizszN	NF:zWJVUSU6JRWK=
RT-112	NGjTZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DaZWlEPTB;MkCuOlEzOiEQvF2=	MnjGV2FPT0WU
CAMA-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\KOGMzUUN3ME2yNE46QDB\|IN88US=>	NYi5Z4FsW0GQR1XS
SW900	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTJzLkCxOFkh\|ryP	Mo\VV2FPT0WU
NCI-H23	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXhTWM2OD1{MT6xNlc4KM7:TR?=	Mk\QV2FPT0WU
SK-PN-DW	M2\MUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTWdIR3UUN3ME2yNU4yPjR7IN88US=>	MlvTV2FPT0WU
BB30-HNC	M3q4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnzfWRKSzVyPUKxMlI4PDVizszN	NYnyUGxyW0GQR1XS
VM-CUB-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTJzLkO1N\|Yh\|ryP	MXzTRW5ITVJ?
IST-MEL1	NYDib5FlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkToTWM2OD1{MT6zOlkzKM7:TR?=	MkDZV2FPT0WU
CTB-1	NEXJ[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTJzLkS3OVUh\|ryP	M2jJcHNCVkeHUh?=
LCLC-103H	NEjhOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LrfmlEPTB;MkKuNVU5OiEQvF2=	NVP5XWlQW0GQR1XS
PANC-03-27	M33BUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jLNmlEPTB;MkKuOVE3QSEQvF2=	NF35cI5USU6JRWK=
HTC-C3	MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHaNG9KSzVyPUKyMlU2PTVizszN	MofpV2FPT0WU
TE-8	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTJ\|LkK1OlUh\|ryP	NHTRdYJUSU6JRWK=
NCI-H292	NVnjdpJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLKTWM2OD1{NT6zOVM3KM7:TR?=	M3vMNHNCVkeHUh?=
COLO-680N	Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDETWM2OD1{NT62N\|I6KM7:TR?=	NFLie4hUSU6JRWK=
KYSE-520	NWiwd2htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV35dIlpUUN3ME2yOU43PDRizszN	NHrGZ3pUSU6JRWK=
NB10	NHLvOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjiTJNZUUN3ME2yOk4{OTF5IN88US=>	M2Hw[3NCVkeHUh?=
NCI-H661	NV:1RVFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTJ4LkS3NVMh\|ryP	MVvTRW5ITVJ?
GMS-10	M2r3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnyZo1KSzVyPUK2Mlg3OzhizszN	NHG2NppUSU6JRWK=
NCI-H2122	NEPIfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVn3bm81UUN3ME2yOk46QTl6IN88US=>	NYXvVGdRW0GQR1XS
OVCAR-8	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHSeo1KSzVyPUK3MlA3OzhizszN	M2C5d3NCVkeHUh?=
DJM-1	NYLaZ3pPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHETppSUUN3ME2yO{4yPDV2IN88US=>	MW\TRW5ITVJ?
UACC-893	M3;zSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fRSGlEPTB;MkeuPVg4QCEQvF2=	MXvTRW5ITVJ?
C8166	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzFTWM2OD1{OD62PVM5KM7:TR?=	NYPqSJR4W0GQR1XS
NCI-H1693	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYD0T5h2UUN3ME2yPE43QTd3IN88US=>	MUnTRW5ITVJ?
TYK-nu	NVz1Xox3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml36TWM2OD1\|MD6wN\|Q2KM7:TR?=	NWT3[GRQW0GQR1XS
SW1710	NHrEfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXS0ZoJQUUN3ME2zNE4yOjZizszN	M{T1SXNCVkeHUh?=
A375	NEHoS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHJW\|dKSzVyPUOwMlMzPDNizszN	NF\sN5dUSU6JRWK=
HMV-II	MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVv5O\|RuUUN3ME2zNU4{PTl{IN88US=>	M1HNcHNCVkeHUh?=
NCI-H2087	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\rdWlEPTB;M{GuOlM2OiEQvF2=	NWfoO2I5W0GQR1XS
CAL-54	M2jyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTNzLkeyOFEh\|ryP	Mk[xV2FPT0WU
HCC70	MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nBdGlEPTB;M{KuNVM5PyEQvF2=	NFfGXmxUSU6JRWK=
ES1	Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzCTWM2OD1\|Mj6zNFYzKM7:TR?=	MnnvV2FPT0WU
NCI-H1355	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTN\|LkKwOEDPxE1?	NEXFPGpUSU6JRWK=
CFPAC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTNd3ZTUUN3ME2zN{4zOzN{IN88US=>	MnTtV2FPT0WU
MKN28	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17WcmlEPTB;M{OuN\|gxQSEQvF2=	MnTEV2FPT0WU
HDLM-2	MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3H5N2lEPTB;M{OuOlk{OSEQvF2=	MoPEV2FPT0WU
PANC-10-05	NHv6c4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPMb2NKSzVyPUO0MlExOTRizszN	NXvWTW45W0GQR1XS
SAS	NV3GN4R5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLrOYRKSzVyPUO0MlQ2PjVizszN	NXPsTpZLW0GQR1XS
HCC1395	M3PYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S2fWlEPTB;M{SuO\|E5PiEQvF2=	MnjlV2FPT0WU
8305C	NHPIUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HaWmlEPTB;M{WuPFQyPSEQvF2=	NWDFepBYW0GQR1XS
KM12	NHjNXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTN4Lke1OFch\|ryP	M2\VXnNCVkeHUh?=
SW1116	NYWy[Wx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\TXWlEPTB;M{euOVk6OiEQvF2=	MXPTRW5ITVJ?
SK-MEL-1	Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvDOWxKSzVyPUO4MlM{QDlizszN	Ml7wV2FPT0WU
HCC2218	NVGybJpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXtR3pxUUN3ME2zPE43PTF7IN88US=>	M1z6Z3NCVkeHUh?=
T84	M1f1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGKw[FRKSzVyPUO4Mlc1ODlizszN	MlixV2FPT0WU
ETK-1	NX\PT4hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTN7LkCyNkDPxE1?	MWLTRW5ITVJ?
COLO-800	M2rRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\kXmlEPTB;M{muN\|g3QCEQvF2=	MVjTRW5ITVJ?
CAL-12T	M4rUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;3PYV5UUN3ME2zPU42OjhzIN88US=>	MX;TRW5ITVJ?
ACN	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmWyTWM2OD12MD60PVEyKM7:TR?=	NXmySmN7W0GQR1XS
SJSA-1	NVrvZZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;YTWM2OD12MT6xOVk3KM7:TR?=	M3rTTHNCVkeHUh?=
PSN1	M2fWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLIW\|VKSzVyPUSxMlE4PDlizszN	MV;TRW5ITVJ?
D-566MG	NXHofmZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4CyTWlEPTB;NEGuNlA5PiEQvF2=	MV3TRW5ITVJ?
EGI-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTR{LkSyPEDPxE1?	NEH3PFhUSU6JRWK=
A204	M3TOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTR{Lk[zPFgh\|ryP	M{PtNXNCVkeHUh?=
Saos-2	M{SxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXrTJNYUUN3ME20Nk45OzZ7IN88US=>	MXTTRW5ITVJ?
SNU-C2B	M3PmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrCTWM2OD12Mz62PFc5KM7:TR?=	NI\QfIFUSU6JRWK=
HLE	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmP3TWM2OD12ND6wPFU3KM7:TR?=	MkX4V2FPT0WU
SW1463	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DBOGlEPTB;NESuPVk4OSEQvF2=	MoLaV2FPT0WU
DSH1	NIjhVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTR3LkCwN\|Mh\|ryP	M{jsc3NCVkeHUh?=
MCF7	NH74Z4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfLTWM2OD12NT61NFUyKM7:TR?=	M4r5SnNCVkeHUh?=
K5	NXrST49nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfL[nlkUUN3ME20OU46PDB3IN88US=>	MljQV2FPT0WU
NCI-H358	M3HmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTR5LkKxOUDPxE1?	NGDScZFUSU6JRWK=
NCI-H2030	M3joe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\OdIVpUUN3ME20O{4zOzd2IN88US=>	MkDvV2FPT0WU
SW948	M1LT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXTVm5KUUN3ME20O{41PjRizszN	NU\xPVZCW0GQR1XS
BALL-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDBPYdLUUN3ME20O{43OTZ6IN88US=>	MoK4V2FPT0WU
TE-9	NFLu[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTR5Lkm1PFEh\|ryP	MmO4V2FPT0WU
SK-N-FI	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1n4[mlEPTB;NEiuNFM2QCEQvF2=	MVHTRW5ITVJ?
KALS-1	NUfnUHRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17GRWlEPTB;NEiuNVI5QSEQvF2=	NGrZTZJUSU6JRWK=
HO-1-N-1	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTR6Lke0OFUh\|ryP	MkTvV2FPT0WU
NCI-H2452	MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjxUVVKSzVyPUS5MlEyPTJizszN	Mn:3V2FPT0WU
OC-314	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTR7Lk[4N\|Qh\|ryP	MW\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	- Collapse Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	- Collapse Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03181126	Active not recruiting	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Active not recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2
NCT02079740	Recruiting	Biological: Navitoclax\|Drug: Trametinib	Advanced Lung Carcinoma\|Advanced Malignant Solid Neoplasm\|Advanced Pancreatic Carcinoma\|Malignant Female Reproductive System Neoplasm\|Metastatic Malignant Solid Neoplasm\|Recurrent Lung Carcinoma\|Recurrent Malignant Solid Neoplasm\|Recurrent Pancreatic Carcinoma\|Stage III Lung Cancer AJCC v7\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Lung Cancer AJCC v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	March 7 2014	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)